Tavneos™ (avacopan) – New orphan drug approval
October 8, 2021 - ChemoCentryx announced the FDA approval of Tavneos (avacopan), as an adjunctive treatment of adult patients with severe active antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids.
Top